Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Total Non-Current Liabilities (2020 - 2025)

Xeris Biopharma Holdings' Total Non-Current Liabilities history spans 6 years, with the latest figure at $361.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 3.06% year-over-year to $361.4 million, compared with a TTM value of $361.4 million through Dec 2025, up 3.06%, and an annual FY2025 reading of $361.4 million, up 3.06% over the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $361.4 million at Xeris Biopharma Holdings, down from $367.7 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $367.7 million in Q3 2025, with the low at $131.8 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $293.9 million, with a median of $321.7 million recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 65.28% in 2022 and then fell 1.24% in 2025.
  • Tracing XERS's Total Non-Current Liabilities over 5 years: stood at $186.6 million in 2021, then soared by 46.65% to $273.6 million in 2022, then increased by 18.6% to $324.5 million in 2023, then rose by 8.06% to $350.7 million in 2024, then increased by 3.06% to $361.4 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Total Non-Current Liabilities are $361.4 million (Q4 2025), $367.7 million (Q3 2025), and $346.2 million (Q2 2025).